Business
Novonesis delivered strong organic sales growth of 7% in 2025
COPENHAGEN, Denmark – February 26, 2026. Novonesis delivered strong organic sales growth of 7% and an adjusted EBITDA margin of 37.1% in 2025. The company expects a good start to 2026 and a good year overall. Ester Baiget, President & CEO: “In 2025, we continued to deliver strong organic sales growth. We achieved 7% growth, an adjusted EBITDA margin of 37.1% and a strong cash flow – despite currency headwinds. Growth was broad-based across sales areas and markets, with particularly strong perfor
About this update from Novonesis A/s Class B
[{"type":"image","alt":"Novonesis (Novozymes A/S)","displaySize":"","headline":null,"caption":"Novonesis (Novozymes A/S)","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":38,"url":"https://media.zenfs.com/en/globenewswire.com/d587064c2241c08df4f2bac0e72e38fb"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/zKklvML9_v1QAJVxEtCwVg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTUzO2NmPXdlYnA-/https://media.zenfs.com/en/globenewswire.com/d587064c2241c08df4f2bac0e72e38fb","width":300,"height":38},"resize_sm":{"url":"https://s.yimg.com/ny/api/res/1.2/zKklvML9_v1QAJVxEtCwVg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTUzO2NmPXdlYnA-/https://media.zenfs.com/en/globenewswire.com/d587064c2241c08df4f2bac0e72e38fb","width":300,"height":38}},"lazy":false},{"type":"text","content":"COPENHAGEN, Denmark – February 26, 2026. Novonesis delivered strong organic sales growth of 7% and an adjusted EBITDA margin of 37.1% in 2025. The company expects a good start to 2026 and a good year overall.","length":208,"tagName":"p"},{"type":"text","content":"Ester Baiget, President & CEO:","length":34,"tagName":"p"},{"type":"blockquote","items":[{"val":[{"type":"text","content":"“In 2025, we continued to deliver strong organic sales growth. We achieved 7% growth, an adjusted EBITDA margin of 37.1% and a strong cash flow – despite currency headwinds. Growth was broad-based across sales areas and markets, with particularly strong performance in Emerging Markets. As a pure biosolutions player, Novonesis uniquely combines deep understanding of customers, innovation leadership and world-class scale capabilities, driving performance and strengthening resilience. In 2026, we expect another good year, with growth across all sales areas and margin expansion. We continue to execute on our strategy, positioning us to firmly deliver on our 2030 targets and beyond."","length":692,"tagName":"p"}]}],"isPullQuote":false,"pullquoteImage":null,"source":"","length":692},{"type":"text","content":"Highlights of our full-year 2025 results:","length":41,"tagName":"p"},{"type":"text","content":"• Broad-based organic sales growth of 7% (Q4: 4%) including the negative impact of exiting certain countries of ~1%-point (Q4: ~2%-points). Price contributed ~1%-point (Q4: ~1%-point) and sales synergies contributed ~1%-point (Q4: ~1%-point).• Food & Health at 8% organic sales growt...